XAIR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the data provided, Beyond Air Inc (XAIR) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows weak technical indicators, mixed financial performance, and lacks significant positive catalysts for immediate growth. Holding the stock or waiting for further developments might be a better approach.
The stock is showing bearish technical indicators. The MACD is negative and contracting (-0.014), the RSI is neutral at 36.164, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 0.924, and resistance is at 1.025. The stock is trading below its pivot point, indicating a downward trend.
The company published a review article highlighting the efficacy of high-dose inhaled nitric oxide (iNO) as a broad-spectrum antimicrobial therapy, which could enhance clinical development and research. Revenue increased significantly by 104.66% YoY in Q3 2026.
The FDA's approval decision for the second-generation LungFit PH system is not expected until the end of 2026, delaying potential commercialization. Net income dropped by 43.71% YoY, EPS fell by 71.28% YoY, and gross margin declined significantly by 168.15% YoY. Analysts have lowered price targets, with one reducing it from $6 to $2.
In Q3 2026, revenue increased by 104.66% YoY to $2,194,000. However, net income dropped to -$7,336,000 (-43.71% YoY), EPS declined to -0.85 (-71.28% YoY), and gross margin fell to 13.67 (-168.15% YoY). The financials show mixed performance with significant profitability challenges.
Analysts have a mixed view. Rodman & Renshaw initiated coverage with a Buy rating and a $5 price target, while JonesResearch reduced the price target from $6 to $2 but maintained a Buy rating. Analysts highlight the potential of the LungFit PH system but note delays in FDA approval as a concern.
